Effervescent Patents (Class 424/466)
-
Patent number: 6436447Abstract: Disclosed is an evacuant possessing a sufficient evacuating effect in a small dose substantially without accompanying any irritation to bowel, irrespective of whether its preparations are in the form of tablets, liquids or elixirs, and having a suppressing action to odor of feces. This evacuant is characterized by containing an active magnesium oxide which has a BET value (surface area in terms of m2/g) of at least 21, preferably 21-50, more preferably 30-40 and is excellent in acid reactivity, and may preferably be incorporated with lactic acid bacteria, a mixture of sporolactobacteria and yeast extracts and/or oligosaccharides. The preparations are preferably in the form of liquids, granules, tablets and capsules.Type: GrantFiled: November 23, 1999Date of Patent: August 20, 2002Assignee: Fujix, Inc.Inventors: Ranko Inoue, Takeshi Inoue, Seiichi Yamagiwa
-
Publication number: 20020110578Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.Type: ApplicationFiled: February 20, 2002Publication date: August 15, 2002Inventors: Sathasivan Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R. Robinson, John Hontz
-
Patent number: 6432450Abstract: The effervescent granules with delayed effervescent effect consist of at least one acid component and one component evolving gas under the action of acid, as well as of active substances, fragrances, plant extracts, vitamins, minerals etc. admixed as needed, the particles of the acid component being coated with—preferably 1 to 30% by weight of—at least one carbonate compound—possibly including a partial reaction—and/or a hydrocolloid. The gas-evolving component consists of alkali hydrogen carbonate, alkali carbonate, and/or alkaline-earth carbonate particles which are coated with at least one further substance, particularly with a melt of polyethylene glycol 6000. The particles preferably have a grain size above 0.2 mm.Type: GrantFiled: September 6, 2000Date of Patent: August 13, 2002Inventors: Gerhard Gergely, Irmgard Gergely, Thomas Gergely
-
Patent number: 6419955Abstract: The present invention relates to a process for the preparation of bisphonate-containing pharmaceutical compositions for oral administration wherein the active substance is wet-granulated in a fluidized-bed granulator and the wet granulate is dried in the fluidised bed granulator. The dried granulate is further processed to produce desired dosage forms.Type: GrantFiled: October 7, 1999Date of Patent: July 16, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Rolf-Dieter Gabel, Jörn Möckel, Heinrich Woog
-
Patent number: 6399099Abstract: The invention relates to effervescent compositions containing a dry extract of ginkgo biloba and an effervescent mixture. By dissolving the mixture in water a virtually clear and almost neutral solution is produced which is stable during the period of use.Type: GrantFiled: September 17, 1997Date of Patent: June 4, 2002Assignee: Dr. Willmar Schwabe GmbH & Co.Inventor: Rainer Oschmann
-
Patent number: 6399086Abstract: The present invention relates to a pharmaceutical controlled-release oral drug delivery system comprising as active ingredient at least one &bgr;-lactam antibiotic agent, having a specific absorption site in the small intestine in combination with a polymeric matrix, optionally further containing additional pharmaceutically acceptable constituents, wherein at least 50% of the &bgr;-lactam antibiotic agent are released from the matrix within from about 3 to about 4 hours from oral administration and the reminder of the pharmaceutical agent is released at a controlled rate. The drug delivery system according to the invention optionally further comprises a &bgr;-lactamase inhibitor, preferably in combination with amoxicillin and/or amoxicillin trihydrate as the active ingredient. The polymeric matrix of the pharmaceutical controlled-release oral drug delivery system of the invention my be of hydrophilic and/or hydrophobic nature and the delivery system may further comprise pharmaceutically acceptable additive.Type: GrantFiled: May 17, 1999Date of Patent: June 4, 2002Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Ifat Katzhendler, Amnon Hoffman, Michael Friedman
-
Patent number: 6391335Abstract: The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.Type: GrantFiled: July 10, 2000Date of Patent: May 21, 2002Assignee: Cima Labs Inc.Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz, Sangeeta V. Gupte
-
Publication number: 20020058070Abstract: A masking agent for pharmaceutical tastes comprises a mixture of a sapid agent and an enhancer, in the form of an intimate mixture. The sapid agent/enhancer distribution is substantially homogeneous and non-statistical. The proportion of sapid agent relative to the enhancer is substantially constant and equal in all powder particles. The masking agent can have a grain size comprised between 10 and 100 &mgr;um, with a Gaussian distribution. The proportion of sapid agent/enhancer is comprised between 97/3 and 90/10, expressed in parts by weight. The sapid agent comprises a sweetener selected from the group comprising sodium saccharinates, calcium saccharinates, saccharine, aspartyl-phenylalanine, acesulfam, cyclamates, stevioside, and mixtures thereof; and the enhancer is selected from the group comprising thaumatin, neohesperidin dihydrochalcone (NHDC), glycyrrhizin, and mixtures thereof. A method of producing a masking agent is also disclosed.Type: ApplicationFiled: October 24, 2001Publication date: May 16, 2002Inventors: Denis Felisaz, Yvan Jacquier
-
Patent number: 6375986Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.Type: GrantFiled: September 21, 2000Date of Patent: April 23, 2002Assignee: Elan Pharma International Ltd.Inventors: Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 6375956Abstract: The present invention relates to a disposable dispensing apparatus which provides optimal therapeutic support to humans and other animals by conveniently supplying a complex dosing regimen requiring simultaneous administration of storage-incompatible or unevenly dosed components in a shelf stable user-friendly format. The present invention is particularly useful for humans with special therapeutic needs, such as pregnant, lactating and/or menopausal women.Type: GrantFiled: July 22, 1999Date of Patent: April 23, 2002Assignee: Drugtech CorporationInventors: Marc S. Hermelin, Mitchell I. Kirschner, Sjoerd Osinga
-
Patent number: 6368625Abstract: A dosage form which rapidly disintegrates in the mouth and forms a viscous slurry of either microcapsules or a powder is described. The rapidly disintegrating dosage form is meant for direct oral administration by placing a tablet or capsule in the mouth of a patient. Upon disintegration, a viscosity of the resulting slurry increases so as to form an organoleptically pleasant viscous material which retards the spread of insoluble materials including the drug.Type: GrantFiled: August 11, 1999Date of Patent: April 9, 2002Assignee: Cima Labs Inc.Inventors: John M. Siebert, Rajendra K. Khankari, Unchalee Kositprapa, S. Indiran Pather
-
Patent number: 6365185Abstract: The present invention relates to tablets which are time-controlled to release active agent at different rates in different regions of the digestive tract in order to maintain a substantially constant concentration in the blood. In one embodiment, a new modified release drug delivery system, for once a day peroral use, consisting of a solid core comprising an active agent together with a hydrogel, with the solid core being coated with a semi-permeable, self-destructing membrane which is optionally drilled to provide a release orifice, and then optionally further coated with the same or different active agent material. The device delivers the active agent in a substantially constant effective dose for the duration of the transit through the stomach and small intestine, followed by accelerated release when reaching the large intestine.Type: GrantFiled: March 26, 1999Date of Patent: April 2, 2002Assignee: University of CincinnatiInventors: Wolfgang A. Ritschel, Mukul A. Agrawal
-
Patent number: 6365182Abstract: The present invention relates to a potassium containing dosage form which is capable of rapidly disintegrating in a patient's mouth to form an easy to swallow slurry.Type: GrantFiled: August 12, 1998Date of Patent: April 2, 2002Assignee: Cima Labs Inc.Inventors: Rajendra K. Khankari, John Hontz, Sara J. Chastain
-
Patent number: 6353031Abstract: A pain relief preparation for use while bathing for soothing and relaxing a user's body. The pain relief preparation for use while bathing includes (A) salts; (B) sodium bicarbonate; (C) an alkaline solution; (D) a bulb; and (E) aromatic seeds for use with water upon a user's body.Type: GrantFiled: June 16, 2000Date of Patent: March 5, 2002Inventor: James L. Dickey, Sr.
-
Patent number: 6350470Abstract: The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.Type: GrantFiled: April 29, 1999Date of Patent: February 26, 2002Assignee: Cima Labs Inc.Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz, Sangeeta V. Gupte
-
Patent number: 6337083Abstract: An oral delivery composition and method are provided for facilitating the swallowing of a solid object such as a pill, tablet, capsule or caplet. The oral delivery composition is made up of a mixture of a base liquid and at least one additive. The additive is selected and is present in the oral delivery composition in a sufficient concentration such that the oral delivery composition has improved physical properties, in comparison with the base liquid, so that when the oral delivery composition and a solid object to be swallowed by a user are administered together to the user and swallowed, the solid object is less likely to become lodged or stuck on tongue, throat, palate or esophageal surfaces of the user, in comparison to when the base liquid and the solid object are administered together and swallowed.Type: GrantFiled: September 29, 2000Date of Patent: January 8, 2002Assignee: International FluidicsInventor: Richard C. Fuisz
-
Patent number: 6328994Abstract: An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 &mgr;m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.Type: GrantFiled: August 4, 1999Date of Patent: December 11, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Toshihiro Shimizu, Shuji Morimoto, Tetsuro Tabata
-
Patent number: 6328993Abstract: Novel administration form for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.Type: GrantFiled: June 22, 2000Date of Patent: December 11, 2001Assignee: Byk Gulden Lomberg Chemische Fabrik GmbHInventors: Rudolf Linder, Rango Dietrich
-
Patent number: 6326360Abstract: An object of the present invention is to obtain an oral glycyrrhizin preparation not only manufacturable by a simple method but also having an excellent property of being absorbed from the digestive tract. In the present invention, such oral preparations are made into enteric forms wherein glycyrrhizin is admixed with an effervescent agent in combination with an absorption enhancer such as a medium-chain fatty acid or a salt thereof. In the preparation of the present invention, it is now possible to achieve an excellent absorption of glycyrrhizin from the digestive tract by addition of an effervescent agent and, moreover, the preparation can be manufactured by a simple, convenient method without special steps.Type: GrantFiled: September 25, 2000Date of Patent: December 4, 2001Assignee: Grelan Pharmaceuticals Co., Ltd.Inventors: Hashime Kanazawa, Kenji Shimizu, Kazuhiro Sasaki, Tetsuya Sugimoto
-
Patent number: 6319683Abstract: A method and composition for quenching formaldehyde fixation of cell and tissue specimens. The composition includes a formaldehyde-reactive agent. The formaldehyde-reactive agent reacts with the formaldehyde to quench the fixation of the cell or tissue specimen. The method involves contacting a formaldehyde fixative solution with the composition.Type: GrantFiled: April 14, 1997Date of Patent: November 20, 2001Assignee: Intergen CompanyInventors: William M. James, Stephen W. Hoag
-
Patent number: 6319514Abstract: The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of: (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or pure (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams.Type: GrantFiled: January 27, 2000Date of Patent: November 20, 2001Assignee: The Boots Company, PLCInventor: Ninh On
-
Patent number: 6294196Abstract: The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.Type: GrantFiled: October 7, 1999Date of Patent: September 25, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Rolf-Dieter Gabel, Walter Preis, Heinrich Woog
-
Patent number: 6294199Abstract: Bacterial infections may be treated using a high dosage regimen of amoxycillin. Preferably, the dosage is provided by a bilayer tablet.Type: GrantFiled: April 6, 2000Date of Patent: September 25, 2001Assignee: Beecham Pharmaceuticals (Pte) LimitedInventors: Creighton P. Conley, John A. Roush, Kevin H. Storm
-
Patent number: 6284272Abstract: A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, wherein the effervescent blend comprises an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermo-hygrometric conditions and with standard tabletting equipment.Type: GrantFiled: March 21, 2000Date of Patent: September 4, 2001Assignee: Chiesi Farmaceutici S.p.A.Inventors: Paolo Chiesi, Paolo Ventura, Rosa Mezzadri, Gaetano Brambilla, Daniela Acerbi
-
Patent number: 6284271Abstract: The present invention is related to an effervescent pharmaceutical preparation comprising effervescent excipients and a plurality of individual units comprising a pharmaceutically active compound and optional excipients wherein the units (1) are provided with a floating generating system. The floating generating systems comprises at least two coating layers, one of which is a gas generating layer (2) and the other layer is a barrier layer (3) enclosing the generated gas. Furthermore the invention is related to a process for the manufacture of the dosage forms, and their use in medicine.Type: GrantFiled: August 28, 1998Date of Patent: September 4, 2001Assignee: AstraZeneca ABInventors: Per Johan Lundberg, Mikael Thune
-
Patent number: 6280770Abstract: Novel pharmaceutical compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel pharmaceutical compositions of the present invention comprise drug-containing microemulsions adsorbed onto solid particles which may be further formulated into solid dosage forms. The compositions and dosage forms of the present invention improve the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.Type: GrantFiled: August 13, 1999Date of Patent: August 28, 2001Assignee: Cima Labs Inc.Inventors: S. Indiran Pather, Sangeeta V. Gupte, Rajendra K. Khankari, John Hontz, Joseph R. Robinson, Jonathan D. Eichman, Ramya Kumbale
-
Patent number: 6274172Abstract: Granulates comprising an effervescent couple of anhydrous powdered monosodium citrate and powdered sodium bicarbonate and prepared using a roller compactor are formulated into pharmaceutical compositions.Type: GrantFiled: September 3, 1998Date of Patent: August 14, 2001Assignee: SmithKline Beecham Laboratoires PharmaceutiquesInventor: Jacky Andre Gustave Mention
-
Patent number: 6264984Abstract: A histamine H2 antagonist incompatible with acidic materials is incorporated in an effervescent composition and is stable therein provided the acidulant employed in the effervescent couple is a non-hydroxy group containing acidulant and such acidulant is employed as substantially the entire amount of the acidulant present in the formulation. Preferably the composition is devoid of hydroxy group containing acidulant. Adipic acid, succinic acid, fumaric acid and succinic anhyride may be employed as the acidulant. Adipic acid is preferred.Type: GrantFiled: December 6, 1999Date of Patent: July 24, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Mamoun M. Hussein, John Migton
-
Patent number: 6261601Abstract: A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.Type: GrantFiled: September 14, 1998Date of Patent: July 17, 2001Assignee: Ranbaxy Laboratories LimitedInventors: Naresh Talwar, Himadri Sen, John N. Staniforth
-
Patent number: 6261600Abstract: The present invention is directed to novel chewable or dissolvable nutritional supplements for improving the absorption of folic acid in humans and other animals and methods of using said supplements. The nutritional supplements contain folic acid and non-toxic acid neutralizing alkaline compounds in chewable or dissolvable forms.Type: GrantFiled: April 30, 1999Date of Patent: July 17, 2001Assignee: DrugTech CorporationInventors: Mitchell I. Kirschner, George Paradissis, R. Saul Levinson
-
Publication number: 20010006677Abstract: According to the present invention, effervescent controlled release water soluble or swellable hot-melt extruded films are provided. Such films comprise a hot-melt extrudable water soluble or swellable binder, an active ingredient, an effervescent couple and optionally another compound such as a plasticizer. The films are made by a hot-melt extrusion process. Bioadhesive effervescent films can also be made by the invention.Type: ApplicationFiled: October 29, 1996Publication date: July 5, 2001Inventors: JAMES W. MCGINITY, JOSEPH R. ROBINSON
-
Patent number: 6251421Abstract: The present invention provides orally administrable pharmaceutical compositions containing an inhibitor of gastrointestinal lipase, and at least one compound selected from the group consisting of psyllium husk, its seeds and leaves thereof. Methods are provided for preventing and treating anal leakage of oil in a patient to whom a composition containing an inhibitor of gastrointestinal lipase is orally administered.Type: GrantFiled: September 25, 2000Date of Patent: June 26, 2001Inventor: Sarfaraz K. Niazi
-
Patent number: 6248363Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.Type: GrantFiled: November 23, 1999Date of Patent: June 19, 2001Assignee: Lipocine, Inc.Inventors: Mahesh V. Patel, Feng-Jing Chen
-
Patent number: 6248760Abstract: A tablet for the transmucosal administration of nicotine. The nicotine is in one or more layers upon a non-nicotine containing matrix. The nicotine layers rapidly dissolve in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces. The short, rapid pulse of nicotine is similar to that given by cigarette smoking. The nicotine may be provided in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine layers.Type: GrantFiled: April 14, 1999Date of Patent: June 19, 2001Inventor: Paul C Wilhelmsen
-
Patent number: 6245353Abstract: The present invention relates to a solid, effervescent, rapidly dissolving dosage form for oral administration, of (a) cetirizine or a pharmaceutically acceptable salt thereof, (b) an effervescent base comprising (i) at least one of (1) an organic edible acid and (2) a salt thereof, (ii) at least one of an alkali metal and an alkaline earth metal carbonate and bicarbonate, and (c) optionally a pharmaceutically acceptable auxiliary ingredient.Type: GrantFiled: March 26, 1999Date of Patent: June 12, 2001Assignee: ASTA Medica AGInventors: Wolfram Tritthart, Mario André Piskering
-
Patent number: 6242002Abstract: The invention relates to an effervescent, rapidly disintegrating oral dosage form of (a) an alkali-sensitive active ingredient, (b) an effervescent base comprising at least one of (i) at least one alkaline earth metal carbonate, (ii) an organic edible acid, and (iii) an alkali metal salt of citric acid, and optionally (c) a pharmaceutically acceptable auxiliary ingredient, and to a process for preparing the dosage form.Type: GrantFiled: March 26, 1999Date of Patent: June 5, 2001Assignee: Arzneimittelwerk Dresden GmbHInventors: Wolfram Tritthart, Mario André Piskernig, Gottfried Kölbl
-
Patent number: 6242000Abstract: The use of S(−)sodium 2-(4-isobutylphenyl)propionate (the sodium salt of S(+)-ibuprofen) in pharmaceutical compositions for the treatment of inflammation, pain and pyrexia is described. Preferred compositions comprise S(−)sodium 2-(4-isobutylphenyl)propionate dihydrate. Processes to prepare S(−)sodium 2-(4-isobutyl-phenyl)propionate and its use in a process to prepare S(+) 2-(4-isobutylphenyl)propionic acid of high enantiomeric purity are also described.Type: GrantFiled: October 2, 1997Date of Patent: June 5, 2001Assignee: The Boots Company PLCInventors: Bernard John Armitage, John Francis Lampard, Alan Smith
-
Patent number: 6225123Abstract: The present invention is an additive preparation for use in bodily fluid collection devices. The additive preparation has an additive, an organic acid and a metal carbonate compound. The preparation effervesces when in contact with a body fluid sample, thereby efficiently dispersing in a body fluid sample. The formulation is desirably tabulated to provide an effective, easily stored, and handled preparation. However, a binding or bulking agent may be added to the additive preparation formulation to provide binding and lubricating properties to the formulation. A binding agent enables granulating of the formulation without the forming of a pellet.Type: GrantFiled: August 14, 1997Date of Patent: May 1, 2001Assignee: Becton Dickinson and CompanyInventors: Richmond R. Cohen, Ajit N. Dastane
-
Patent number: 6217933Abstract: The invention relates to a method for treating a denture, comprising passing the denture through the air interface of an aqueous composition comprising a polymeric coating agent, especially a silicone polymer, having a weight average molecular weight of 1,000 or greater.Type: GrantFiled: July 15, 1999Date of Patent: April 17, 2001Assignee: The Procter & Gamble CompanyInventors: Mark Ieuan Edwards, Iain Allan Hughes
-
Patent number: 6210711Abstract: The invention concerns multilayer microspheres containing an acid substance, a basic substance, and a water-soluble isolating agent which, when it dissolves in water, after almost instant effervescence, brings about a homogeneous dispersion of active principal(s) which is present in the acid and basic substances. The invention also concerns a method for preparing such microspheres by rotational granulation on a fluid air bed associated with a system of tangential spraying of the wetting liquid.Type: GrantFiled: August 13, 1999Date of Patent: April 3, 2001Assignee: Pierre Fabre MedicamentInventors: Jean-Marc Aiache, Pascale Gauthier, Joël Bougaret
-
Patent number: 6207191Abstract: A drug delivery system (10) includes a first capsule half (12) having an inner chamber (16) containing a drug (18) therein. A plug (28) is disposed in a passageway (26) of the capsule half (12) for plugging the opening (24) thereof. The plug (28) is releasable from the passageway opening (24) upon the application of pressure from within the inner chamber (16). A pump mechanism, reactive with the external environment of the capsule half (12), causes an increase in pressure within the inner chamber (16) and forces the plug (28) out of the passageway (26) to release the drug (18) from the inner chamber (16) and out of the passageway (26). Thusly, after initial release of drug from a second capsule half (14) releasably mounted on the first capsule half (12), the first capsule half (12) provides a second pulse of drug release at a predetermined time after initial ingestion of the capsule.Type: GrantFiled: August 12, 1999Date of Patent: March 27, 2001Assignee: Port Systems, L.L.C.Inventors: John R. Crison, Gordon L. Amidon
-
Patent number: 6203817Abstract: Transdermal compositions, devices, and methods for the administration of a drug at reduced skin irritation levels are disclosed. More particularly, this invention relates to novel methods, compositions, and devices for the reduction or elimination of irritation or sensitization caused by an irritating or sensitizing drug when it is delivered transdermally. According to a preferred embodiment, transdermal administration of a drug salt of a non-zwitterionic drug is disclosed wherein the drug salt comprises a combination of surface activity and a low octanol-water partition coefficient. Such drug salts have been found to reduce irritation or sensitization to the drug being delivered while achieving therapeutically effective transdermal fluxes.Type: GrantFiled: June 5, 1998Date of Patent: March 20, 2001Assignee: ALZA CorporationInventors: Michel J. N. Cormier, Peter E. Daddona, Juanita A. Johnson
-
Patent number: 6200604Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.Type: GrantFiled: June 8, 1999Date of Patent: March 13, 2001Assignee: Cima Labs Inc.Inventors: Sathasivan Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R. Robinson, John Hontz
-
Patent number: 6197329Abstract: The present disclosure is directed to novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using same. The compositions provide improved relief from nausea and/or vomiting. The compositions are particularly useful for pregnant women.Type: GrantFiled: May 3, 1999Date of Patent: March 6, 2001Assignee: Drugtech CorporationInventors: Marc S. Hermelin, Mitchell I. Kirschner, R. Saul Levinson
-
Patent number: 6197336Abstract: An analgesic composition useful in the preparation of fast dissolving tablets is provided, where the composition is the result of combining ibuprofen, arginine, linear PVP and an alkaline bicarbonate to which usual excipients for the preparation of tablets are added.Type: GrantFiled: May 26, 1999Date of Patent: March 6, 2001Assignee: Zambon Group S.p.A.Inventors: Alessandro Grassano, Maurizio Marchiorri, Mauro Di Toro, Franco Castegini
-
Patent number: 6197338Abstract: The present invention relates to a new type of solid balneological preparations for cosmetic, hygienic and therapeutic use, which has both the properties of a solid bath additive and those of liquid products, and is characterized especially by the addition of lipid components, vesicle forming lipids, tensides and, in some cases, mineral salts. Active components, adjuvants such as stabilizers, adsorbing substances, lubricants as well as smoothing and breakdown promoting agents may also be contained therein.Type: GrantFiled: January 12, 2000Date of Patent: March 6, 2001Assignee: Merz & Co. GmbH & Co.Inventors: Eberhard Nürnberg, Kerstin Jerzembek, Rolf D. Beutler, Jürgen Ebinger, Ruth Weis
-
Patent number: 6190697Abstract: The effervescent formulation elation in the form of granules or of a tablet contains, in addition to the effervescent base, at least one water-soluble or at least suspendable plant extract whose particles are coated with at least one oily, fatty or waxy substance. At least one emulsifier and/or at least one antifoam may be present in the coating and/or as a further component of the mixture, in particular applied as a further component of the mixture to a pharmaceutically permissible filler as carrier. The individual phases are prepared by a procedure in which the plant extract or the filler is heated—preferably in a granulator, in particular in a vacuum granulator—and wet or mixed with a melt or solution of the oily, fatty or waxy substance or at least one emulsifier and/or at least one antifoam and then dried—preferably in a vacuum—and sieved to the desired particle size.Type: GrantFiled: October 26, 1998Date of Patent: February 20, 2001Inventors: Gerhard Gergely, Irmgard Gergely, Thomas Gergely, Stefan Gergely
-
Patent number: 6187337Abstract: A particulate support matrix, and a dosage form made therefrom, and processes for making such support matrices and dosage forms, which disintegrate or dissolve in a matter of just a few seconds once placed into an aqueous environment. First, a porous particulate powder matrix comprising at least two polymeric components which will serve as the dosage form matrix is produced. The polymeric components have different solubilities. In a second step, a pharmaceutical compound, for example an antihistamine, decongestant, or antibiotic is combined with the powder. Other additives may also be added to the mixture. In a third step the mixture is formed into a dosage form. Finally, in a fourth step, a coating may be formed upon the outer surface of the dosage form to enhance the intactness and durability of the dosage form.Type: GrantFiled: July 6, 1998Date of Patent: February 13, 2001Assignees: The Board of Regents of the University of Oklahoma, Janssen PharmaceuticaInventors: Loyd V. Allen, Bingnan Wang, John Desmond Davies
-
Patent number: 6177104Abstract: A particulate support matrix, and a dosage form made therefrom, and processes for making such support matrices and dosage forms, which disintegrate or dissolve in a matter of just a few seconds once placed into an aqueous environment. First, a porous particulate powder matrix comprising at least two polymeric components which will serve as the dosage form matrix is produced. The polymeric components have different solubilities. In a second step, a pharmaceutical compound, for example an antihistamine, decongestant, or antibiotic is combined with the powder. Other additives may also be added to the mixture. In a third step the mixture is formed into a dosage form. Finally, in a fourth step, a coating may be formed upon the outer surface of the dosage form to enhance the intactness and durability of the dosage form.Type: GrantFiled: July 6, 1998Date of Patent: January 23, 2001Assignee: The Board of Regents of the University of OklahomaInventors: Loyd V. Allen, Bingnan Wang
-
Patent number: 6171617Abstract: In particular, the invention relates to a new, clearly dissolving ibuprofen effervescent formulation and a process for the preparation of this formulation. Ibuprofen or (±)2-(4-isobutylphenyl)-propionic acid has the following structural formula and has been for years a proven, non-steroidal antiphlogistic from the group of phenylpropionic acid derivatives, which shows effectiveness in veterinary experimental inflammation models by inhibiting prostaglandin synthesis.Type: GrantFiled: January 6, 1999Date of Patent: January 9, 2001Assignee: Losan Pharma GmbHInventor: Peter Gruber